Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
With
Daiichi Sankyo
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has one of the following cancers:
* Unresectable or metastatic colorectal cancer.
* Advanced and/or unresectable biliary tract cancer (BTC)
* Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
* Locally advanced unresectable or metastatic gastroesophageal cancer
Has received prior therapy for the cancer.
Has recovered from any side effects due to previous cancer treatment
You may not be if
Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
Has evidence of any leptomeningeal disease
Has clinically significant corneal disease
Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
Clareo Health | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
